NCT05309668 · OUTCOME
Parent-to-metabolite Ratio for AUC0-6, AUC0-12 and AUC0-24 After Single and Multiple Dose Administration.
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN · Source last updated 2026-08-13
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- Ratio
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Pre-dose and 1, 2, 3, 4, 6, 8, 10-12 and 18-24 hours after selumetinib single dose on Cycle 1 Day 1. Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)
What was measured
To further evaluate the PK of the granule formulation.
Analysis population: Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.
Groups in this outcome
Global Cohort 1
Global Cohort 1 (\>=4 to \<7 years)
Global Cohort 2
Global Cohort 2 (\>=1 to \<4 years)
Total in Global
Global Cohorts (\>=1 to \<7 years)
Japan Cohort
Japan Cohort (\>=1 to \<7 years)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 15 |
|---|
| Global Cohort 2 | 17 |
|---|
| Total in Global | 32 |
|---|
| Japan Cohort | 4 |
|---|
Reported measurements
Cycle 1 Day 1: MPAUC0-6
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 13 |
|---|
| Global Cohort 2 | 15 |
|---|
| Total in Global | 28 |
|---|
| Japan Cohort | 4 |
|---|
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Global Cohort 1 | 0.07803 | 18.27 | Not reported | Not reported | Not reported |
|---|
| Global Cohort 2 | 0.07379 | 15.50 | Not reported | Not reported | Not reported |
|---|
| Total in Global | 0.07573 | 16.76 | Not reported | Not reported | Not reported |
|---|
| Japan Cohort | 0.07386 | 12.37 | Not reported | Not reported | Not reported |
|---|
Cycle 1 Day 1: MPAUC0-12
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 13 |
|---|
| Global Cohort 2 | 13 |
|---|
| Total in Global | 26 |
|---|
| Japan Cohort | 4 |
|---|
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Global Cohort 1 | 0.08204 | 17.91 | Not reported | Not reported | Not reported |
|---|
| Global Cohort 2 | 0.07722 | 17.19 | Not reported | Not reported | Not reported |
|---|
| Total in Global | 0.07960 | 17.48 | Not reported | Not reported | Not reported |
|---|
| Japan Cohort | 0.07742 | 14.05 | Not reported | Not reported | Not reported |
|---|
Cycle 1 Day 1: MPAUC0-24
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 13 |
|---|
| Global Cohort 2 | 13 |
|---|
| Total in Global | 26 |
|---|
| Japan Cohort | 3 |
|---|
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Global Cohort 1 | 0.08209 | 19.94 | Not reported | Not reported | Not reported |
|---|
| Global Cohort 2 | 0.07516 | 18.93 | Not reported | Not reported | Not reported |
|---|
| Total in Global | 0.07855 | 19.59 | Not reported | Not reported | Not reported |
|---|
| Japan Cohort | 0.07942 | 7.881 | Not reported | Not reported | Not reported |
|---|
Cycle 2 Day 1: MPAUC0-6
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 15 |
|---|
| Global Cohort 2 | 14 |
|---|
| Total in Global | 29 |
|---|
| Japan Cohort | 4 |
|---|
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Global Cohort 1 | 0.06036 | 29.62 | Not reported | Not reported | Not reported |
|---|
| Global Cohort 2 | 0.06123 | 26.61 | Not reported | Not reported | Not reported |
|---|
| Total in Global | 0.06078 | 27.69 | Not reported | Not reported | Not reported |
|---|
| Japan Cohort | 0.06934 | 20.71 | Not reported | Not reported | Not reported |
|---|
Cycle 2 Day 1: MPAUC0-12
Analysis denominator · Participants
| Group | Source count |
|---|
| Global Cohort 1 | 14 |
|---|
| Global Cohort 2 | 14 |
|---|
| Total in Global | 28 |
|---|
| Japan Cohort | 4 |
|---|
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Global Cohort 1 | 0.06413 | 29.74 | Not reported | Not reported | Not reported |
|---|
| Global Cohort 2 | 0.06429 | 26.09 | Not reported | Not reported | Not reported |
|---|
| Total in Global | 0.06421 | 27.42 | Not reported | Not reported | Not reported |
|---|
| Japan Cohort | 0.07339 | 19.13 | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 18.27
- value
- 0.07803
- group Id
- OG001
- spread
- 15.50
- value
- 0.07379
- group Id
- OG002
- spread
- 16.76
- value
- 0.07573
- group Id
- OG003
- spread
- 12.37
- value
- 0.07386
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 15
- group Id
- OG002
- value
- 28
- group Id
- OG003
- value
- 4
- units
- Participants
- title
- Cycle 1 Day 1: MPAUC0-6
- categories
- measurements
- group Id
- OG000
- spread
- 17.91
- value
- 0.08204
- group Id
- OG001
- spread
- 17.19
- value
- 0.07722
- group Id
- OG002
- spread
- 17.48
- value
- 0.07960
- group Id
- OG003
- spread
- 14.05
- value
- 0.07742
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 13
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 4
- units
- Participants
- title
- Cycle 1 Day 1: MPAUC0-12
- categories
- measurements
- group Id
- OG000
- spread
- 19.94
- value
- 0.08209
- group Id
- OG001
- spread
- 18.93
- value
- 0.07516
- group Id
- OG002
- spread
- 19.59
- value
- 0.07855
- group Id
- OG003
- spread
- 7.881
- value
- 0.07942
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 13
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 3
- units
- Participants
- title
- Cycle 1 Day 1: MPAUC0-24
- categories
- measurements
- group Id
- OG000
- spread
- 29.62
- value
- 0.06036
- group Id
- OG001
- spread
- 26.61
- value
- 0.06123
- group Id
- OG002
- spread
- 27.69
- value
- 0.06078
- group Id
- OG003
- spread
- 20.71
- value
- 0.06934
- denoms
- counts
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 14
- group Id
- OG002
- value
- 29
- group Id
- OG003
- value
- 4
- units
- Participants
- title
- Cycle 2 Day 1: MPAUC0-6
- categories
- measurements
- group Id
- OG000
- spread
- 29.74
- value
- 0.06413
- group Id
- OG001
- spread
- 26.09
- value
- 0.06429
- group Id
- OG002
- spread
- 27.42
- value
- 0.06421
- group Id
- OG003
- spread
- 19.13
- value
- 0.07339
- denoms
- counts
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 14
- group Id
- OG002
- value
- 28
- group Id
- OG003
- value
- 4
- units
- Participants
- title
- Cycle 2 Day 1: MPAUC0-12
- denoms
- counts
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 17
- group Id
- OG002
- value
- 32
- group Id
- OG003
- value
- 4
- units
- Participants
- description
- To further evaluate the PK of the granule formulation.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Global Cohort 1 (\>=4 to \<7 years)
- id
- OG000
- title
- Global Cohort 1
- description
- Global Cohort 2 (\>=1 to \<4 years)
- id
- OG001
- title
- Global Cohort 2
- description
- Global Cohorts (\>=1 to \<7 years)
- id
- OG002
- title
- Total in Global
- description
- Japan Cohort (\>=1 to \<7 years)
- id
- OG003
- title
- Japan Cohort
- param Type
- GEOMETRIC_MEAN
- population Description
- Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.
- reporting Status
- POSTED
- time Frame
- Pre-dose and 1, 2, 3, 4, 6, 8, 10-12 and 18-24 hours after selumetinib single dose on Cycle 1 Day 1. Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)
- title
- Parent-to-metabolite Ratio for AUC0-6, AUC0-12 and AUC0-24 After Single and Multiple Dose Administration.
- type
- SECONDARY
- unit Of Measure
- Ratio
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice